skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 70  for All Library Resources

Results 1 2 3 4 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors
Material Type:
Article
Add to My Research

Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors

Endocrine-related cancer, 2016-09, Vol.23 (9), p.759-767 [Peer Reviewed Journal]

2016 Society for Endocrinology ;2016 Society for Endocrinology. ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-16-0147 ;PMID: 27552969

Full text available

2
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
Material Type:
Article
Add to My Research

A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood

Annals of oncology, 2020-02, Vol.31 (2), p.202-212 [Peer Reviewed Journal]

2019 European Society for Medical Oncology ;Copyright © 2019 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. ;ISSN: 0923-7534 ;ISSN: 1569-8041 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2019.11.003 ;PMID: 31959337

Full text available

3
Analysis of the immune landscape of small bowel neuroendocrine tumors
Material Type:
Article
Add to My Research

Analysis of the immune landscape of small bowel neuroendocrine tumors

Endocrine-related cancer, 2019-01, Vol.26 (1), p.119-130 [Peer Reviewed Journal]

2018 Society for Endocrinology ;Copyright Society for Endocrinology & BioScientifica Ltd. Jan 2019 ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-18-0189 ;PMID: 30400003

Full text available

4
O-20 Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
Material Type:
Article
Add to My Research

O-20 Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer

Annals of oncology, 2020-07, Vol.31, p.239 [Peer Reviewed Journal]

ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2020.04.073

Full text available

5
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
Material Type:
Article
Add to My Research

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms

ESMO open, 2022-02, Vol.7 (1), p.100364-100364, Article 100364 [Peer Reviewed Journal]

2021 The Authors ;Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. ;2021 The Authors 2021 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2021.100364 ;PMID: 34973511

Full text available

6
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
Material Type:
Article
Add to My Research

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

Endocrine-related cancer, 2015-02, Vol.22 (1), p.1-9 [Peer Reviewed Journal]

2015 Society for Endocrinology ;2015 Society for Endocrinology. ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-14-0360 ;PMID: 25376618

Full text available

7
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors
Material Type:
Article
Add to My Research

A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors

Annals of oncology, 2012-09, Vol.23 (9), p.2335-2341 [Peer Reviewed Journal]

2012 European Society for Medical Oncology ;2015 INIST-CNRS ;The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2012 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdr614 ;PMID: 22317769

Full text available

8
A phase II study of axitinib in advanced neuroendocrine tumors
Material Type:
Article
Add to My Research

A phase II study of axitinib in advanced neuroendocrine tumors

Endocrine-related cancer, 2016-05, Vol.23 (5), p.411-418 [Peer Reviewed Journal]

2016 Society for Endocrinology ;2016 Society for Endocrinology. ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-16-0008 ;PMID: 27080472

Full text available

9
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
Material Type:
Article
Add to My Research

Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors

ESMO open, 2024-04, Vol.9 (4), p.102386-102386, Article 102386 [Peer Reviewed Journal]

2024 The Authors ;Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. ;2024 The Authors 2024 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1016/j.esmoop.2024.102386 ;PMID: 38507897

Full text available

10
Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
Material Type:
Article
Add to My Research

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Annals of oncology, 2018-10, Vol.29, p.viii467-viii468 [Peer Reviewed Journal]

2018 THE AUTHORS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdy293.001 ;PMID: 32137198

Full text available

11
A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients
Material Type:
Article
Add to My Research

A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients

Annals of oncology, 2012-05, Vol.23 (5), p.1335-1340 [Peer Reviewed Journal]

2012 European Society for Medical Oncology ;2015 INIST-CNRS ;The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2012 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdr442 ;PMID: 21994214

Full text available

12
The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)
Material Type:
Article
Add to My Research

The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)

Annals of oncology, 2018-10, Vol.29, p.viii473-viii473 [Peer Reviewed Journal]

2018 THE AUTHORS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdy293.015 ;PMID: 32137216

Full text available

13
Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study
Material Type:
Article
Add to My Research

Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study

Annals of oncology, 2018-10, Vol.29, p.viii471-viii471 [Peer Reviewed Journal]

2018 THE AUTHORS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdy293.009 ;PMID: 32137209

Full text available

14
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors
Material Type:
Article
Add to My Research

A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors

Endocrine-related cancer, 2013-06, Vol.20 (3), p.383-390 [Peer Reviewed Journal]

2013 Society for Endocrinology ;2013 Society for Endocrinology 2013 ;ISSN: 1351-0088 ;EISSN: 1479-6821 ;DOI: 10.1530/ERC-12-0390 ;PMID: 23572164

Full text available

15
Pancreatic NETs: where do we stand now?
Material Type:
Article
Add to My Research

Pancreatic NETs: where do we stand now?

Cancer and metastasis reviews, 2014-03, Vol.33 (1), p.361-366 [Peer Reviewed Journal]

Springer Science+Business Media New York 2014 ;COPYRIGHT 2014 Springer ;ISSN: 0167-7659 ;EISSN: 1573-7233 ;DOI: 10.1007/s10555-013-9466-0 ;PMID: 24452757 ;CODEN: CMRED4

Full text available

16
Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma
Material Type:
Article
Add to My Research

Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma

Current oncology (Toronto), 2016-02, Vol.23 (1), p.e70-74 [Peer Reviewed Journal]

2016 Multimed Inc. 2016 ;ISSN: 1198-0052 ;ISSN: 1718-7729 ;EISSN: 1718-7729 ;DOI: 10.3747/co.23.2711 ;PMID: 26966416

Full text available

17
Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors
Material Type:
Article
Add to My Research

Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors

The New England journal of medicine, 2017-01, Vol.376 (2), p.125 [Peer Reviewed Journal]

ISSN: 1533-4406 ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1607427

Full text available

18
PD-2 Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
Material Type:
Article
Add to My Research

PD-2 Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer

Annals of oncology, 2021-07, Vol.32, p.S199 [Peer Reviewed Journal]

ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2021.05.020

Full text available

19
897P HORMONET: Phase II trial of tamoxifen for patients (pts) with estrogen/progesterone receptor (ER/PR)-positive neuroendocrine tumors (NET)
Material Type:
Article
Add to My Research

897P HORMONET: Phase II trial of tamoxifen for patients (pts) with estrogen/progesterone receptor (ER/PR)-positive neuroendocrine tumors (NET)

Annals of oncology, 2022-09, Vol.33, p.S958 [Peer Reviewed Journal]

ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1016/j.annonc.2022.07.1023

Full text available

20
Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population
Material Type:
Article
Add to My Research

Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population

Annals of oncology, 2019-10, Vol.30, p.v564-v565 [Peer Reviewed Journal]

ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz256.002

Full text available

Results 1 - 20 of 70  for All Library Resources

Results 1 2 3 4 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (68)

Refine My Results

Creation Date 

From To
  1. Before 2007  (5)
  2. 2007 To 2010  (11)
  3. 2011 To 2014  (17)
  4. 2015 To 2019  (31)
  5. After 2019  (7)
  6. More options open sub menu

Searching Remote Databases, Please Wait